Maxalt Rpd (Rizatriptan Benzoate)

Rizatriptan works by selectively stimulating 5‑HT1B and 5‑HT1D serotonin receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade.

The prescribed dose of Maxalt Rpd is determined by a qualified healthcare professional based on individual needs, severity of migraine, and medical history. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety of rizatriptan in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Maxalt Rpd.

To order Maxalt Rpd, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both rizatriptan and sumatriptan belong to the triptan class and act on the same serotonin receptors. Rizatriptan often has a faster onset of relief and may be preferred for patients who need rapid symptom control, while individual response varies and should be guided by a clinician.

Store Maxalt Rpd at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Maxalt Rpd is an orally disintegrating tablet. Place the tablet on the tongue; it will dissolve rapidly without the need for water. Swallow the dissolved medication as soon as it disappears, preferably at the first sign of a migraine.

Serious risks include chest pain or tightness indicating possible coronary vasospasm, serotonin syndrome when combined with other serotonergic drugs, and severe allergic reactions such as rash, swelling or breathing difficulty. Patients experiencing these symptoms should seek immediate medical attention.

Maxalt Rpd should be avoided by individuals with uncontrolled hypertension, significant cardiovascular disease (e.g., recent heart attack, angina, stroke), peripheral vascular disease, or those taking MAO inhibitors or other triptans. Consultation with a healthcare provider is essential before starting therapy.